Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $17.18, but opened at $16.19. Mesoblast shares last traded at $16.35, with a volume of 120,019 shares trading hands.
Analyst Ratings Changes
MESO has been the topic of a number of recent research reports. Maxim Group raised Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. Finally, Piper Sandler raised their target price on shares of Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $13.50.
Get Our Latest Stock Analysis on Mesoblast
Mesoblast Price Performance
The stock's fifty day simple moving average is $13.42 and its 200-day simple moving average is $9.57. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.
Institutional Trading of Mesoblast
A number of institutional investors have recently bought and sold shares of MESO. Jane Street Group LLC grew its stake in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after acquiring an additional 26,959 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Mesoblast in the second quarter valued at $562,000. Lazari Capital Management Inc. grew its position in shares of Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock valued at $364,000 after purchasing an additional 3,300 shares during the period. XY Capital Ltd acquired a new position in Mesoblast in the third quarter valued at $244,000. Finally, Creative Planning acquired a new stake in Mesoblast in the 3rd quarter worth about $147,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
